LaurenAverett(Averett)ByersMD

PubMed

• Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer.
  Sehhoon Park, Tae Hee Hong, Soohyun Hwang, Simon Heeke, Carl M Gay, Jiyeon Kim, Hyun-Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Jong Ho Cho, Yong Soo Choi, Jhin...> ;Ebiomedicine. 2024 Apr 1
• Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
  Barzin Y Nabet, Habib Hamidi, Myung Chang Lee, Romain Banchereau, Stefanie Morris, Leah Adler, Velimir Gayevskiy, Ahmed M Elhossiny, Minu K Srivastava, Namrata S Patil...> ;Cancer Cell. 2024 Mar 11
• Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From-Mutant NSCLC Informs Potential Therapeutic Targets.
  Bingnan Zhang, Whitney Lewis, C Allison Stewart, Benjamin B Morris, Luisa M Solis, Alejandra Serrano, Yuanxin Xi, Qi Wang, Elyse R Lopez, Kyle Concannon, Simon Heeke, ...> ;JTO Clinical and Research Reports. 2024 Feb 1
• 1 citations
  Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes.
  Simon Heeke, Carl M Gay, Marcos R Estecio, Hai Tran, Benjamin B Morris, Bingnan Zhang, Ximing Tang, Maria Gabriela Raso, Pedro Rocha, Siqi Lai, Edurne Arriola, Paul Ho...> ;Cancer Cell. 2024 Feb 12
• Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
  Wang, K., Du, R., Myall, N., Lewis, W., Uy, N., Hong, L., Skoulidis, F., Byers, L., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M., Gibbons, D., Park, K., R...> ;Journal of Thoracic Oncology. 2024 Mar 1
• Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and et...
  Stephen V Liu, Tony S K Mok, Barzin Y Nabet, Aaron S Mansfield, Richard De Boer, György Losonczy, Shunichi Sugawara, Rafal Dziadziuszko, Maciej Krzakowski, Alexey Smol...> ;Lung Cancer. 2023 Dec 1
• 1 citations
  Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies.
  Zsolt Megyesfalvi, Simon Heeke, Benjamin J Drapkin, Anna Solta, Ildiko Kovacs, Kristiina Boettiger, Lilla Horvath, Busra Ernhofer, Janos Fillinger, Ferenc Renyi-Vamos,...> ;Cancer Cell. 2023 Sep 11
• 2 citations
  Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Re...
  Di Zhou, Lauren A Byers, Beate Sable, Marie-Anne Damiette Smit, Nooshin Hashemi Sadraei, Sandeep Dutta, Vijay V Upreti> ;Journal of Clinical Pharmacology. 2024 Mar 1
• 24 citations
  Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions.
  Zsolt Megyesfalvi, Carl M Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, ...> ;CA. 2023 Jun 17
• 3 citations
  Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
  Kavya Ramkumar, Azusa Tanimoto, Carminia M Della Corte, C Allison Stewart, Qi Wang, Li Shen, Robert J Cardnell, Jing Wang, Urszula M Polanska, Courtney Andersen, Jamal...> ;Clinical Cancer Research. 2023 Aug 15
• 1 citations
  Novel therapeutic strategies for recurrent SCLC.
  Laura Moliner, Bingnan Zhang, Giuseppe Lamberti, Andrea Ardizzoni, Lauren A Byers, Raffaele Califano> ;Critical Reviews in Oncology/hematology. 2023 Jun 1
• 39 citations
  Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
  Tina Cascone, Cheuk H Leung, Annikka Weissferdt, Apar Pataer, Brett W Carter, Myrna C B Godoy, Hope Feldman, William N William Jr, Yuanxin Xi, Sreyashi Basu, Jing Jing...> ;Nature Medicine. 2023 Mar 1
• 3 citations
  BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
  Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia Tsimberidou, Maria Cabanillas, Naifa...> ;NPJ Precision Oncology. 2023 Feb 18
• 7 citations
  Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
  Kyle Concannon, Benjamin B Morris, Carl M Gay, Lauren A Byers> ;Molecular Cell. 2023 Mar 2
• Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events.
  Mehmet Altan, Quan-Zhen Li, Qi Wang, Natalie I Vokes, Ajay Sheshadri, Jianjun Gao, Chengsong Zhu, Hai T Tran, Saumil Gandhi, Mara B Antonoff, Stephen Swisher, Jing Wan...> ;Frontiers in Immunology. 2023 Jan 1
• 3 citations
  Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
  Carminia Maria Della Corte, Vincenza Ciaramella, Kavya Ramkumar, Giovanni Vicidomini, Alfonso Fiorelli, Valerio Nardone, Salvatore Cappabianca, Immacolata Cozzolino, F...> ;Journal of Translational Medicine. 2022 Nov 22
• 5 citations
  Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial.
  Yufei Liu, Luyang Yao, Neda Kalhor, Brett W Carter, Mehmet Altan, George Blumenschein, Lauren A Byers, Frank Fossella, Don L Gibbons, Jonathan M Kurie, Charles Lu, Fer...> ;Lung Cancer. 2022 Dec 1
• 15 citations
  DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
  James Yao, Emily Bergsland, Rahul Aggarwal, Ana Aparicio, Himisha Beltran, Judy S Crabtree, Christine L Hann, Toni Ibrahim, Lauren A Byers, Hironobu Sasano, John Umeji...> ;The Oncologist. 2022 Nov 3
• 33 citations
  Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
  Yasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, Mehmet Altan, Hai Tran, Don L Gibbons, Simon Heeke, Frank V Fossella, Vincent K Lam, Xiuning Le, Marcelo V Negra...> ;Cancer Cell. 2022 Jul 11
• 3 citations
  Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited...
  Andreas Rimner, Wei-Chu Victoria Lai, Raffaele Califano, Salma K Jabbour, Charles M Rudin, Corinne Faivre-Finn, Byoung Chul Cho, Terufumi Kato, Jinming Yu, Wyatt Chafi...> ;Clinical Lung Cancer. 2022 Jul 1
• 2 citations
  Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set.
  Stephanie T Schmidt, Neal Akhave, Ryan E Knightly, Alexandre Reuben, Natalie Vokes, Jianhua Zhang, Jun Li, Junya Fujimoto, Lauren A Byers, Beatriz Sanchez-Espiridion, ...> ;JCO Clinical Cancer Informatics. 2022 Jul 1
• 1 citations
  Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma.
  Runzhe Chen, Jun Li, Junya Fujimoto, Lingzhi Hong, Xin Hu, Kelly Quek, Ming Tang, Akash Mitra, Carmen Behrens, Chi-Wan Chow, Peixin Jiang, Latasha D Little, Curtis Gum...> ;Journal of Experimental & Clinical Cancer Research. 2022 May 11
• 6 citations
  Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
  Bingnan Zhang, C Allison Stewart, Qi Wang, Robert J Cardnell, Pedro Rocha, Junya Fujimoto, Luisa M Solis Soto, Runsheng Wang, Veronica Novegil, Peter Ansell, Lei He, L...> ;British Journal of Cancer. 2022 Aug 1
• 7 citations
  Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
  Carminia Maria Della Corte, Morena Fasano, Vincenza Ciaramella, Flora Cimmino, Robert Cardnell, Carl M Gay, Kavya Ramkumar, Lixia Diao, Raimondo Di Liello, Giuseppe Vi...> ;Journal of Experimental & Clinical Cancer Research. 2022 Mar 26
• 13 citations
  SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer
  Kiran Kundu, Robert J. Cardnell, Bingnan Zhang, Li Shen, C. Allison Stewart, Kavya Ramkumar, Kasey R. Cargill, Jing Wang, Lauren Averett Byers> ;Translational Lung Cancer Research. 2021 Dec 1
• Join now to see all

Journal Articles

• Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies Across Platinum-Resistant Cancers  
  Faye M Johnson, John V Heymach, Lauren Averett Byers, Clinical Cancer Research

Lectures

• Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC). 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019